Immorta Bio Inc, a scientific longevity company dedicated to „Treating Diseases of Aging and Treating Aging as Disease“ announced today results of laboratory experiments, covered in newly filed patent # 63/789,097 entitled „Augmentation of Natural Killer Cell Number and Activity by Senolytic Therapies“, showing that reducing the number of aged cells known as „senescent cells“ result in a potent increase in numbers and activity of natural killer (NK) cells.
Immorta Bio has previously demonstrated that its SenoVax™ immunotherapy product reduced senescent cells1, increase efficacy of checkpoint inhibitors and chemotherapy2, as well as stimulate regenerative activity of endogenous stem cells in rats3. SenoVax is currently under development as a therapy for lung cancer.
NK cells are believed to play a fundamental role in the ability of the body to fight cancer and viruses. Studies have shown that higher numbers of NK cells infiltrating tumors results in longer survival in breast4, lung5, brain6, and pancreatic7 cancers. Additionally, patients with higher activity of NK cells have superior ability to overcome viral infections.
